The Oncologist, Vol. 1, No. 5, 336–336,
October 1996
© 1996 AlphaMed Press
SPECIAL SECTION
PATIENT CARE |
From The Bethesda Post
 |
ABSTRACT
|
|---|
The Oncologist is pleased to feature news FROM THE BETHESDA POST, featuring high-priority National Cancer Institute clinical trials which are now accruing patients at the National Institutes of Health Clinical Center. There will be information on how to refer patients who may benefit from experimental cancer treatments. Once accepted on protocol, participating patients receive experimental treatment as well as travel to Bethesda free of charge.
Watch for forthcoming POSTS from Berlin, Amsterdam, Boston and around the globe in future issues of The Oncologist.
|
New Vaccine Studies in Cervical Cancer
|
|---|
The intramural clinical program in Bethesda is sponsoring a number of new studies exploring the role of vaccines in cancer treatment. Some of these take advantage of the recent linkage of cervical cancer with human papilloma virus (HPV), while others specifically target mutated oncogenes, such as ras or p53.
For example, HPV genes and their proteins are found in more than 90% of human cervical cancer. The genes E6 and E7 have been particularly implicated in the malignant transformation of normal cervical cells, and represent the oncogenic products of the virus. In addition, there is laboratory evidence that peptide products of these genes can be processed and recognized by human T cells, the cells responsible for tissue rejection in man. For this reason, we are studying whether the HPV E6 and E7 proteins can be targets for specific peptide vaccination.
Patients eligible for the trials include: patients with metastatic (Stage 4), recurrent or inadequately treated Stage 3 disease for therapeutic intent and patients with advanced local disease (Stage 3), appropriately treated, for adjuvant intent. The cost of all therapy as well as travel to and from Bethesda is covered for patients on study.
For more information, or for patient referral, contact Dr. Samir Khleif at telephone: 301-496-0901; fax: 301-496-0047; e-mail: khleif{at}nih.gov
Top
Abstract
New Vaccine Studies in...
